Ansa Biotechnologies
Emeryville, California, United States · Biotechnology · 73 employees
Ansa Biotechnologies is redefining DNA synthesis with a bold commitment to quality, customer satisfaction, and success. The Ansa On-Time Guarantee is simple and straightforward: your complete order on time or it’s free. This unprecedented level of service reliability and predictability is made possible by Ansa’s dedicated team of experts and proprietary enzymatic synthesis platform, which can rapi
Funding history
- Funding Round — $46.4M — Dec 2025
- Funding Round — $45.2M — Oct 2025
- Series series b — $54.4M — Oct 2025
- Funding Round — $5.0M — Oct 2021
- Series seed — $46.4M — Jul 2020
Recent signals
- Mar 31, 2026: Ansa Biotechnologies Appoints Matthias Arenskötter as Chief Operating Officer
- Dec 10, 2025: Raised $46.4M
- Dec 09, 2025: Ansa Biotechnologies Appoints Geoff Hamilton as Chief Financial Officer and Chief Business Officer
- Oct 02, 2025: Raised $45.2M
- Oct 01, 2025: Raised $54.4M in Series series b
- Feb 22, 2024: Ansa Biotechnologies Appoints Jason T. Gammack as CEO and Prepares for Launch of Rapid Enzymatic Synthesis Service for Complex DNA Sequences
- Oct 15, 2021: Raised $5.0M
- Jul 09, 2020: Raised $46.4M in Series seed
See plans & pricing → Track Ansa Biotechnologies’s funding, hiring, and signals — with verified contacts — on Fundz.